Billionaire Stanley Druckenmiller’s Top 10 Stocks Picks with Huge Upside Potential

2. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)

Upside Potential as of April 11: 191.48%

Duquesne Capital’s Stake Value: $7.39 million

Number of Hedge Fund Holders: 36

NewAmsterdam Pharma Company NV (NASDAQ:NAMS) is a biopharmaceutical company that develops treatments for people with cardiovascular diseases (CVDs). Its main product is obicetrapib, a pill designed to lower “bad” cholesterol (LDL-C). The target clients are healthcare providers and patients at risk of heart disease due to high cholesterol.

NewAmsterdam Pharma Company N.V.’s (NASDAQ:NAMS) financials strengthened in the full year 2024. Revenue for the year increased significantly from $14.1 million in 2023 to $45.6 million. The cash position also strengthened to $834.2 million. Nonetheless, the firm’s net loss from operations was higher in 2024 (at $241.6 million) compared to $176.9 million in 2023.

The year was transformative for the company, with Phase 3 trials of obicetrapib showing durable LDL-C reductions—33% in the BROADWAY trial, 49% in the TANDEM trial, and 36% in the BROOKLYN trial—positioning it for an anticipated EMA submission in partnership with Menarini. Confidence in the firm grew, as Director James Topper purchased 1,135 shares worth $25,514, while institutional investors, like Swiss National Bank, increased their holdings by 105.1% in Q4 2024 to 72,000 shares valued at $1.85 million.